A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
NCT03600909
Terminated
The goal of this study is to see if the study therapy can decrease the chemotherapy-related side effects while maximizing the effectiveness of disease control. The physicians will also be studying the effect of removing T-cells from the donor"s stem cells before transplant. T-cells are a type of white blood cell that may help cause a serious side effect of transplant called Graft versus Host Disease (GVHD). The way it removes the T-cells from the donor stem cells is actually by selecting only th... Read More
Gender:
ALL
Ages:
1 month and above
Trial Updated:
03/21/2022
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +2 locations
Conditions: Fanconi Anemia, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Register for Updates
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
NCT02293109
Completed
This phase I trial studies the side effects and best dose of carfilzomib when given together with the hyperfractionated (hyper)-cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, and dexamethasone (CVAD) chemotherapy regimen in treating patients with newly diagnosed acute lymphoblastic leukemia or lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfat... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
03/08/2022
Locations: University of California Davis, Sacramento, California
Conditions: Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
Register for Updates
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
NCT02873819
Completed
This is a multi-center, randomized, double-blind clinical trial to assess the safety and efficacy of GL-0817 as a means to prevent disease recurrence in patients considered at high-risk following surgery and adjuvant chemoradiotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: University of Maryland Greenebaum Cancer Center, Baltimore, Maryland +32 locations
Conditions: Squamous Cell Carcinoma of the Oral Cavity
Register for Updates
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
NCT00667329
Completed
The goal of this clinical research study is to see how well the drugs 2CdA, cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's macroglobulinemia. After these drugs are given for 2 courses, a second goal is to see how long a remission lasts. A third goal is to see how often repeat remissions can be achieved when the lymphoma returns later and the same drugs are restarted. This is an investigational study. The FDA has approved each of these drugs for the treatment of... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2022
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
NCT02111850
Completed
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. In this protocol, we are modifying the patien... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/02/2022
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer
Register for Updates
SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide
NCT02953340
Completed
The purpose of this study is to compare the efficacy of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC) as measured by the duration of severe neutropenia (DSN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: ACRC/ Arizona Clinical Research Center Inc., Tucson, Arizona +73 locations
Conditions: Neutropenia, Breast Cancer
Register for Updates
SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)
NCT02643420
Completed
The purpose of this study was to compare the efficacy of a single dose of SPI-2012 versus pegfilgrastim in participants with early-stage breast cancer receiving docetaxel and cyclophosphamide (TC), as measured by the duration of severe neutropenia (DSN) in Cycle 1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2022
Locations: Arizona Center for Cancer Care, Glendale, Arizona +80 locations
Conditions: Neutropenia, Breast Cancer
Register for Updates
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
NCT04893915
Withdrawn
Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will receive lymphodepleting chemotherapy (Flu/Cy) and two infusions of cytokine-induced memory-like NK cells at the previously defined maximum tolerated dose (MTD), fourteen days apart. Low dose rhIL-2 will be administered to patients for in vivo expansion following cell infusion. Patients will be assessed for anti-leukemic efficacy and safety. Re-infusion of patients who relapsed after clinical res... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
NCT00193479
Completed
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent administration of rituximab it is likely to be as effective as longer programs, and will certainly be better tolerated by this patient group. The addition of maintenance therapy may result in substantial prolongation of remission duration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2022
Locations: Florida Cancer Specialists, Fort Myers, Florida +1 locations
Conditions: Non-Hodgkins Lymphoma
Register for Updates
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
NCT02481310
Unknown
The purpose of this study is to evaluate the effects, good and bad of a new drug called ixazomib (also called MLN9708), when it is given along with a common treatment combination, called Dose-Adjusted EPOCH-R (DA-EPOCH-R, for short). This is a type of study called a phase I/II trial. In the phase I part, the dose of the study drug (ixazomib) will be adjusted (either up or down) to find the maximum (highest) dose that does not cause excessive (too many) harmful side effects. In the phase II part,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2022
Locations: Northwestern University, Chicago, Illinois +4 locations
Conditions: Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
Register for Updates
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
NCT02354547
Suspended
The purpose of this study is to determine the dose limiting toxicities and recommended phase 2 dose of SGT-53 alone and in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory solid tumors.
Gender:
ALL
Ages:
Between 12 months and 21 years
Trial Updated:
02/07/2022
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Neoplasm
Register for Updates
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
NCT01453140
Terminated
In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/04/2022
Locations: John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Graft Versus Host Disease
Register for Updates